title: Microwave coagulation therapy for hepatocellular carcinoma.
abstract: The efficacy and safety of microwave coagulation therapy (MCT) in patients with hepatocellular carcinoma (HCC) and impaired hepatic reserve were studied. Preoperative background factors, postoperative results, and prognostic factors were compared in 51 patients who underwent hepatic resection (HR group) and 38 patients who underwent microwave coagulation therapy (MCT group). Before surgery, measures of hepatic function, including level of albumin (P = 0.0072), prothrombin time (P<0.0001), hepaplastin test (P = 0.0088), and the radioactivity of technetium-99m galactosyl-human serum albumin 15 min in the liver after injection divided by that in both liver and heart (P <0.0001) were significantly lower in the MCT group than in the HR group. The indocyanine green dye retention rate at 15 min was significantly greater (P<0.0001) in the MCT group than in the HR group, and a significant difference was noted in Child-Pugh grade between the groups (P<0.0001). Operative time (P = 0.0014) and blood loss during surgery (P = 0.0005) were significantly lower in the MCT group than in the HR group. In contrast, no significant differences were recognized between the groups in the changes in postoperative liver function, or in the rates of morbidity, mortality, local recurrence, and survival. Moreover, the type of treatment (HR or MCT) was not a prognostic factor. The results indicate that MCT can be used safely as an alternative to hepatic resection in patients with poor liver function without reducing the efficacy of local control.
authors.affiliation: Department of Surgery, Showa University Fujigaoka Hospital, 1-30 Fujigaoka, Aoba-ku, Yokohama 227-8501, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Midorikawa
authors.forename: K
authors.initials: K
authors.lastname: Kumada
authors.forename: H
authors.initials: H
authors.lastname: Kikuchi
authors.forename: K
authors.initials: K
authors.lastname: Ishibashi
authors.forename: H
authors.initials: H
authors.lastname: Yagi
authors.forename: H
authors.initials: H
authors.lastname: Nagasaki
authors.forename: H
authors.initials: H
authors.lastname: Nemoto
authors.forename: M
authors.initials: M
authors.lastname: Saitoh
authors.forename: H
authors.initials: H
authors.lastname: Nakano
authors.forename: M
authors.initials: M
authors.lastname: Yamaguchi
authors.forename: Y
authors.initials: Y
authors.lastname: Koh
authors.forename: H
authors.initials: H
authors.lastname: Sakai
authors.forename: Y
authors.initials: Y
authors.lastname: Yoshizawa
authors.forename: Y
authors.initials: Y
authors.lastname: Sanada
authors.forename: M
authors.initials: M
authors.lastname: Yoshiba
mesh_terms: D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000000981:diagnostic imaging / Q000401:mortality / Q000601:surgery*; D004564:Electrocoagulation / Q000379:methods*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007813:Laparotomy / Q000379:methods*; D008111:Liver Function Tests; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000401:mortality / Q000601:surgery*; D008297:Male; D008872:Microwaves / Q000627:therapeutic use*; D008875:Middle Aged; D015999:Multivariate Analysis; D011336:Probability; D016016:Proportional Hazards Models; D015996:Survival Rate; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome